EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations

Fehime Erdem iD, Ebru Canda iD, Havva Yazıcı iD, Rabia Eser iD, Merve Yoldaş Çelik iD, Selcan Keşan iD, Merve Saka Güvenç iD, Tahir Atik iD, İpek Tamsel iD, Hüseyin Onay iD, Sema Kalkan Uçar iD, Eser Yıldırım Sözmen iD und 1 weitere

Journal of Pediatric Endocrinology and Metabolism · 2025

DOI: 10.1515/jpem-2025-0352 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2025. Verfasst von Fehime Erdem und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Metabolism and Nutrition, 60521 Ege University Faculty of Medicine , Izmir, Türkiye. Hauptthemen laut MEDLINE: Mucolipidoses, Mutation, Transferases (Other Substituted Phosphate Groups). Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Mucolipidosis (ML) type II α/β (I-cell disease) and type III (Pseudo-Hurler polydystrophy) are rare autosomal recessive lysosomal storage disorders caused by mutations in the GNPTAB (ML III α/β) and GNPTG (ML III γ) genes, leading to impaired lysosomal enzyme trafficking. These disorders manifest as progressive multisystem diseases with skeletal, neurological, cardiovascular, and respiratory involvement. This study aims to characterise pediatric patients’ clinical, biochemical, genetic, and radiological findings with ML II α/β and IIIα/β or γ to enhance understanding of disease diagnosis and progression.

Methods

This retrospective cohort study included 19 pediatric patients (15 ML II α/β, 3 ML III γ, 1 ML III α/β) diagnosed at a tertiary referral center. Clinical data, including facial dysmorphism, skeletal abnormalities, organomegaly, cardiovascular involvement, and neurological findings, were recorded at baseline and follow-up. Biochemical analysis included urinary glycosaminoglycan (GAG) levels and lysosomal enzyme activities. For molecular diagnostics, next-generation sequencing (NGS) was utilized using a targeted gene panel that contained GNPTG and GNPTAB leukocytes from peripheral blood were used to harvest genomic DNA. Following the 2015 ACMG/AMP standards, variant interpretation was carried out by evaluating pathogenicity using in silico prediction methods, population frequency data, and segregation analysis. Radiological findings were evaluated via skeletal X-rays and brain MRI.

Results

The median age at diagnosis was 8 months (range: 1 day–252 months), with a consanguinity rate of 63.1 %. ML II α/β patients presented earlier and had more severe findings, including coarse facies, respiratory tract involvement, cardiac abnormalities, and joint contractures. Cardiac valve disease, kyphosis, and progressive hearing loss were frequent. The most common mutation in GNPTAB was c.3503_3504delTC in ML II α/β, while GNPTG variants were linked to ML III γ. Radiologic findings often included hip dysplasia; brain MRIs showed callosal and subarachnoid abnormalities in a few cases. Median survival in ML II α/β was 28 months, mainly due to respiratory failure. Enzyme assays revealed elevated β-hexosaminidase A and A+B, α-D-mannosidase, and α-L-fucosidase activities in both leukocyte and DBS samples, consistent with molecular diagnoses.

Conclusions

In addition to reporting six novel GNPTAB/GNPTG mutations, this study highlights the diagnostic potential of dried blood spot (DBS) samples, where elevated lysosomal enzyme activity may offer a valuable, minimally invasive screening method for ML II/III.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MucolipidosesMutationTransferases (Other Substituted Phosphate Groups)HumansMaleFemaleChildRetrospective StudiesChild, PreschoolInfantPrognosisFollow-Up StudiesAdolescentLongitudinal Studies

Stichwörter der Autor:innen

GNPTABGNPTGlysosomal storage disordermucolipidosisskeletal dysplasia

Substanzen

Transferases (Other Substituted Phosphate Groups)GNPTAB protein, humanGNPTG protein, human

Autor:innen und Institutionen

  • Department of Pediatrics, Division of Metabolism and Nutrition, 60521 Ege University Faculty of Medicine , Izmir, Türkiye.
  • Department of Medical Genetics, Izmir City Hospital, Izmir, Türkiye.
  • Department of Pediatrics, Division of Genetics, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Radiology, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Medical Genetics, Ege University Faculty of Medicine, Izmir, Türkiye.
  • Department of Biochemistry, Izmir Tınaztepe University Faculty of Medicine, Izmir, Türkiye.

ORCID-Profile: Fehime Erdem, Ebru Canda, Havva Yazıcı, Rabia Eser, Merve Yoldaş Çelik, Selcan Keşan, Merve Saka Güvenç, Tahir Atik, İpek Tamsel, Hüseyin Onay, Sema Kalkan Uçar, Eser Yıldırım Sözmen, Mahmut Çoker

Zitieren

APA

Erdem, F., Canda, E., Yazıcı, H., Eser, R., Yoldaş Çelik, M., Keşan, S., Saka Güvenç, M., Atik, T., Tamsel, İ., Onay, H., Kalkan Uçar, S., Sözmen, E. Y., & Çoker, M. (2025). Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2025-0352

Vancouver

Erdem F, Canda E, Yazıcı H, Eser R, Yoldaş Çelik M, Keşan S, et al. Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations. Journal of Pediatric Endocrinology and Metabolism. 2025. doi:10.1515/jpem-2025-0352

BibTeX
@article{Erdem2025,
  author = {Erdem, Fehime and Canda, Ebru and Yazıcı, Havva and Eser, Rabia and Yoldaş Çelik, Merve and Keşan, Selcan and Saka Güvenç, Merve and Atik, Tahir and Tamsel, İpek and Onay, Hüseyin and Kalkan Uçar, Sema and Sözmen, Eser Yıldırım and Çoker, Mahmut},
  title = {Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations},
  journal = {Journal of Pediatric Endocrinology and Metabolism},
  year = {2025},
  doi = {10.1515/jpem-2025-0352}
}
Kostenlos starten →